Top searches



B2RLaw advises Auxilius Pharma on capital raise to fuel groundbreaking growth to the US market


B2RLaw advised Auxilius Pharma Sp. z o.o. and its founders on a venture capital transaction related to the investment of Cofounder Zone Corporate Angel Fund ASI, AUGEBIT Closed Investment Fund, and several business angels and current partners at Auxilius.

With the new funds, the Company will be able to further develop its flagship  project involving introduction of a Value Added Medication cardiological drug to the US market, as well as other drug development projects.

Auxilius Pharma was founded by Jędrzej Litwiniuk and Uwe Tigör in 2019 and is a fast-growing pharmaceutical early stage company with a focus on further developing and optimizing medications well established in some markets but not in others. The Company is currently focused on the development of cardiovascular medicine which is available in the EU but not in the US. Auxilius Pharma has reformulated the drug into a once-daily product in an effort to improve convenience and compliance of patients. Earlier this year, the Company get the nod of the American Food and Drug Administration (FDA) for the clinical development plan of its cardiovascular drug. The Agency agreed to use an expedite, 505(b)2 regulatory pathway for the product, which will allow a speedy and cost-effective regulatory pathway.

B2R’s team was led by Krystyna Jakubowska (Advocate, Senior Associate), who was supported by Teresa Pilecka-Juda (Attorney-at-law, Senior Associate) and Magdalena Zawiślak (Junior Associate). Rafal Stroiński (Advocate, Senior Partner) oversaw B2R’s team. SSW Pragmatic Solutions advised Cofounder Zone, who was represented by Tomasz Goliński and Michał Sioda.

Krysia Jakubowska advises, “we are extremely pleased to have assisted Auxilius Pharma on this exciting transaction. With Poland being one of global leaders in cardiac treatment, it is pleasing to advise on a transaction which provides Auxilius and its founders with the funds which will allow it to continue developing its cardiovascular drug with the view of bringing this effective medication to US patients and clinicians. ”

View more resources

Catch up on the very latest B2RLAW
announcements and news here.


Danyila Zubach on WEB3: Impact The Economy Summit

WEB3: Impact the Economy was a discussion about the realities and opportunities of WEB3economy. It gathered policymakers, founders, CEOs of […]


B2RLaw in the Bay Area and Silicon Valley on 24th October – 1st November

Here we go again on our US roadshow! Meet us in the Bay and Area Silicon Valley on 24th October […]


B2RLaw advised Everfield UK Limited in the acquisition of 100% of the shares of a Polish start-up – Grafik Optymalny

Everfield is an international IT group that invests in companies with specialized software that solves operational problems for businesses. They […]


B2RLaw advises Vestas on the acquisition of the ST3 Offshore for over PLN 170 million

B2RLaw advises Vestas on the acquisition of the ST3 Offshore for over PLN 170 million. Vestas, the Danish global giant […]


B2RLaw’s team advised IQ Biozoom in connection with the investment support received from VC Link

B2RLaw’s team advised IQ Biozoom in connection with the investment support received from VC Link. IQ Biozoom is a Polish […]


Julia Stroińska at the Modern Lawyer’s Conference “Law and Technology in the 21st Century”

Today at the Modern Lawyer’s Conference ”Law and Technology in the 21st Century“, organised by the Center for American Studies Poland, Julia Stroińska, Junior […]


Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.